| Dr Daniel Benton Verrill, MD | |
|
3700 Southern Blvd Ste 300, Kettering, OH 45429-1226 | |
| (937) 643-9299 | |
| (937) 643-2343 |
| Full Name | Dr Daniel Benton Verrill |
|---|---|
| Gender | Male |
| Speciality | Interventional Pain Management |
| Experience | 13 Years |
| Location | 3700 Southern Blvd Ste 300, Kettering, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447543525 | NPI | - | NPPES |
| 0159828 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 35.122951 (Ohio) | Secondary |
| 208VP0014X | Pain Medicine - Interventional Pain Medicine | 35.122951 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kettering Medical Center - Sycamore | Miamisburg, OH | Hospital |
| Troy Hospital | Troy, OH | Hospital |
| Grandview And Southview Hospitals | Dayton, OH | Hospital |
| Kettering Medical Center | Kettering, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kettering Independent Medical Group Inc | 3173710936 | 586 |
News Archive
Ever get a flu shot and still get the flu? If so, there's new hope for flu-free winters in the years to come thanks to a new discovery by researchers who found that a drug called DMXAA, originally developed as anti-tumor agent, enhances the ability of flu vaccines to ward off this deadly virus.
Aggressive prostate cancer, one of the leading causes of cancer deaths in men, is associated with BRCA2 mutations, which are also linked to hereditary breast cancer, ovarian cancer and pancreas cancer, among others.
Zytoprotec, a company developing drugs based on active cytoprotection, today announced the completion of a Phase I/II clinical trial with its lead product, PD-protec.
QLT Inc. ("QLT" or the "Company") is pleased to announce the establishment of its commercial presence in the United States through a newly formed U.S. subsidiary, QLT Ophthalmics, Inc. ("QOI"). QOI will take on the sales and marketing of Visudyne(R) in the U.S.
A new meta-analysis of more than 135,000 people with major depression and more than 344,000 controls has identified 44 genomic variants, or loci, that have a statistically significant association with depression.
› Verified 6 days ago
| Entity Name | Alliance Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437125572 PECOS PAC ID: 0840104360 Enrollment ID: O20031118000529 |
News Archive
Ever get a flu shot and still get the flu? If so, there's new hope for flu-free winters in the years to come thanks to a new discovery by researchers who found that a drug called DMXAA, originally developed as anti-tumor agent, enhances the ability of flu vaccines to ward off this deadly virus.
Aggressive prostate cancer, one of the leading causes of cancer deaths in men, is associated with BRCA2 mutations, which are also linked to hereditary breast cancer, ovarian cancer and pancreas cancer, among others.
Zytoprotec, a company developing drugs based on active cytoprotection, today announced the completion of a Phase I/II clinical trial with its lead product, PD-protec.
QLT Inc. ("QLT" or the "Company") is pleased to announce the establishment of its commercial presence in the United States through a newly formed U.S. subsidiary, QLT Ophthalmics, Inc. ("QOI"). QOI will take on the sales and marketing of Visudyne(R) in the U.S.
A new meta-analysis of more than 135,000 people with major depression and more than 344,000 controls has identified 44 genomic variants, or loci, that have a statistically significant association with depression.
› Verified 6 days ago
| Entity Name | Kettering Independent Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629387865 PECOS PAC ID: 3173710936 Enrollment ID: O20101207000425 |
News Archive
Ever get a flu shot and still get the flu? If so, there's new hope for flu-free winters in the years to come thanks to a new discovery by researchers who found that a drug called DMXAA, originally developed as anti-tumor agent, enhances the ability of flu vaccines to ward off this deadly virus.
Aggressive prostate cancer, one of the leading causes of cancer deaths in men, is associated with BRCA2 mutations, which are also linked to hereditary breast cancer, ovarian cancer and pancreas cancer, among others.
Zytoprotec, a company developing drugs based on active cytoprotection, today announced the completion of a Phase I/II clinical trial with its lead product, PD-protec.
QLT Inc. ("QLT" or the "Company") is pleased to announce the establishment of its commercial presence in the United States through a newly formed U.S. subsidiary, QLT Ophthalmics, Inc. ("QOI"). QOI will take on the sales and marketing of Visudyne(R) in the U.S.
A new meta-analysis of more than 135,000 people with major depression and more than 344,000 controls has identified 44 genomic variants, or loci, that have a statistically significant association with depression.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Daniel Benton Verrill, MD 3700 Southern Blvd Ste 300, Kettering, OH 45429-1226 Ph: (937) 643-9299 | Dr Daniel Benton Verrill, MD 3700 Southern Blvd Ste 300, Kettering, OH 45429-1226 Ph: (937) 643-9299 |
News Archive
Ever get a flu shot and still get the flu? If so, there's new hope for flu-free winters in the years to come thanks to a new discovery by researchers who found that a drug called DMXAA, originally developed as anti-tumor agent, enhances the ability of flu vaccines to ward off this deadly virus.
Aggressive prostate cancer, one of the leading causes of cancer deaths in men, is associated with BRCA2 mutations, which are also linked to hereditary breast cancer, ovarian cancer and pancreas cancer, among others.
Zytoprotec, a company developing drugs based on active cytoprotection, today announced the completion of a Phase I/II clinical trial with its lead product, PD-protec.
QLT Inc. ("QLT" or the "Company") is pleased to announce the establishment of its commercial presence in the United States through a newly formed U.S. subsidiary, QLT Ophthalmics, Inc. ("QOI"). QOI will take on the sales and marketing of Visudyne(R) in the U.S.
A new meta-analysis of more than 135,000 people with major depression and more than 344,000 controls has identified 44 genomic variants, or loci, that have a statistically significant association with depression.
› Verified 6 days ago
Lauren Aleice Stroud, Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 3700 Southern Blvd Ste 300, Kettering, OH 45429 Phone: 937-643-9299 Fax: 937-643-2343 |